ArticleAmerican journal of translational research2026
Optimization of an integrated traditional Chinese and western medicine regimen for thin endometrium using motherwort injection combined with different doses of CPET - evaluating endometrial receptivity and clinical pregnancy outcomes.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThin endometrium (TE) is an important factor associated with embryo implantation failure and adverse pregnancy outcomes during assisted reproductive treatment. This study investigated the clinical efficacy of fixed-dose motherwort injection (MI) combined with different doses of compound estradiol/dydrogesterone tablets (CPET) in the treatment of TE, evaluated its effects on endometrial receptivity, and determined the optimal therapeutic dose of CPET.
methodsA retrospective propensity score-matched cohort study was conducted. Patients with TE treated between August 2024 and October 2025 were included. After 1:1:1 PSM, patients were matched into a control group, a low-dose CPET group, and a high-dose CPET group, with 58 patients in each group. The control group received MI alone, whereas the low- and high-dose CPET groups received different doses of CPET in addition to MI. The intervention lasted for three consecutive cycles. Endometrial morphology and hemodynamic parameters were assessed by transvaginal ultrasonography. Serum sex hormones and cytokines were measured by ELISA, and peripheral-blood mRNA expression of receptivity-related genes was detected by qPCR as an exploratory systemic molecular marker. Clinical pregnancy outcomes, safety, and cost-effectiveness were also analyzed.
resultsAfter treatment, all three groups showed improvements in endometrial thickness, endometrial volume, the proportion of type A endometrium, and blood perfusion. The high-dose group exhibited the greatest improvement, followed by the low-dose group and the control group. In the high-dose group, serum VEGF, IGF-1, and LIF levels increased, whereas TGF-β1 levels decreased; meanwhile, peripheral-blood mRNA expression levels of ITGAV, ITGB3, HOXA10, SPP1, and KDR increased in a dose-dependent manner (
conclusionMI combined with low- or high-dose CPET may improve endometrial receptivity and pregnancy outcomes in patients with TE. In this retrospective cohort, the high-dose regimen showed favorable short-term efficacy, tolerability, and cost-effectiveness. However, further studies using endometrial tissue samples are required to verify protein-level changes and the specific signaling pathways underlying the observed clinical effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.